Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (449)	6/16/1999 2:59:00 AM
From: scaram(o)uche	Respond to of 3158

David: The NPY5 project is with Novartis, so I doubt that even SNAP knows how it's going. There's a second obesity project with Lilly, focused on one of the serotonin receptors (I don't know one from the other). I think that they'd make a great gobble, if you're not concerned with near-term revenues. MLNM certainly emphasized G Protein-Coupled Receptors. Very much undervalued, IMO, since the migraine hit. However, it wouldn't be considered as a glaring target, as potential royalties (modest, I believe) would flow from Merck, Lilly, Grunenthal, etc. Rick